Zevra Therapeutics (ZVRA) Current Assets (2014 - 2026)
Zevra Therapeutics' (ZVRA) quarterly Current Assets came in at $230.0 million in Q1 2026, up 181.92% YoY from $81.6 million in Q1 2025, and up 3.12% on a QoQ basis from $223.0 million in Q4 2025.
Zevra Therapeutics (ZVRA) Current Assets (2014 - 2026) Analysis & Trends
Zevra Therapeutics (ZVRA) has 13 years of Current Assets data on file, last reported at $230.0 million in Q1 2026.
- Quarterly Current Assets rose 181.92% year-over-year to $230.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $230.0 million (up 181.92% YoY) and the FY2025 annual result came in at $223.0 million, up 159.23% from the prior year.
- Current Assets grew to $230.0 million in Q1 2026, from $223.0 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $230.0 million in Q1 2026 to a low of $60.9 million in Q2 2024.
- A 5-year average of $123.3 million and a median of $99.4 million in 2024 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2024 — Current Assets slumped 41.13% — and 2025, when it soared 271.71%.
- Tracing ZVRA's Current Assets over 5 years: stood at $92.8 million in 2022, then slipped by 6.35% to $86.9 million in 2023, then declined by 1.05% to $86.0 million in 2024, then jumped by 159.23% to $223.0 million in 2025, then climbed by 3.12% to $230.0 million in 2026.
- The last three Current Assets figures came in at $230.0 million (Q1 2026), $223.0 million (Q4 2025), and $225.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Zevra Therapeutics | 671.75 Mn | 450.18 Mn | 38.18 Mn | 251.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 251.30 Mn |
| Mar 31, 2026 | 229.97 Mn |
| Dec 31, 2025 | 223.01 Mn |
| Sep 30, 2025 | 225.12 Mn |
| Jun 30, 2025 | 226.34 Mn |
| Mar 31, 2025 | 81.57 Mn |
| Dec 31, 2024 | 86.03 Mn |
| Sep 30, 2024 | 99.44 Mn |
| Jun 30, 2024 | 60.89 Mn |
| Mar 31, 2024 | 62.89 Mn |
| Dec 31, 2023 | 86.94 Mn |
| Sep 30, 2023 | 137.01 Mn |
| Jun 30, 2023 | 103.43 Mn |
| Mar 31, 2023 | 104.28 Mn |
| Dec 31, 2022 | 92.83 Mn |
| Sep 30, 2022 | 84.71 Mn |
| Jun 30, 2022 | 87.01 Mn |
| Mar 31, 2022 | 105.35 Mn |
| Dec 31, 2021 | 115.06 Mn |
| Sep 30, 2021 | 134.63 Mn |